AstraZeneca has stopped selling Andexxa, a factor Xa inhibitor anticoagulant reversal agent the FDA first approved in 2018, because patients may face an increased risk of experiencing a blood clot or stroke. The company emphasized that it remains confident in the agent's abilities.
The Volt Pulsed Field Ablation System from Abbott has been approved by the FDA. The technology, which gained CE mark approval in March, features a one-of-a-kind catheter design and allows patients to be treated under conscious sedation.
Patients first sued the St. Louis Park, Minnesota-based imaging group in two separate lawsuits, both filed in 2023, over its use of tracking pixels to allegedly filter info to Facebook and other third parties.
Founded in 2023, Hunterbrook is an investigative news and investment outlet, which creates reports criticizing publicly traded companies and then benefits from the corresponding drop in share prices
The U.S. Department of Justice has formally accused Done Global of unlawfully distributing ADHD medications without medical need, using a subscription program and targeted advertising to find patients searching for drugs. The company is also accused of filing false medical claims to Medicare, Medicaid and commercial insurance. Done's founder and CEO was convicted last month on related charges and awaits sentencing.
Drug distributors AmerisourceBergen (Cencora), Cardinal Health, McKesson, Johnson & Johnson, Teva and Allergan do not admit to wrongdoing. However, they have agreed to a settlement which will compensate providers for opioid abuse treatments.
After a bout of COVID-19, an 81-year-old woman developed bed sores that became infested with maggots. A lawsuit claims the facility failed to take proper action to treat the injury.
AstraZeneca has stopped selling Andexxa, a factor Xa inhibitor anticoagulant reversal agent the FDA first approved in 2018, because patients may face an increased risk of experiencing a blood clot or stroke. The company emphasized that it remains confident in the agent's abilities.
The Volt Pulsed Field Ablation System from Abbott has been approved by the FDA. The technology, which gained CE mark approval in March, features a one-of-a-kind catheter design and allows patients to be treated under conscious sedation.
